EGF released from human placental mesenchymal stem cells improves premature ovarian insufficiency via NRF2/HO-1 activation.

ABSTRACT: Human placental mesenchymal stem cells (hPMSCs) have the ability to release cytokines and to differentiate into the three germ layers. To date, the relevance of hPMSCs for the treatment of premature ovarian insufficiency (POI) disease through the regulation of oxidative stress is still unclear. Therefore, to evaluate the therapeutic efficiency and investigate the mechanism of hPMSCs, we generated a mouse model of POI and collected human ovarian granule cells (hGCs) from patients with POI. hPMSCs displayed therapeutic effects on POI ovarian function, including recovered follicular numbers and increased expression of oocyte markers. Furthermore, secretion of the cytokine EGF (epidermal growth factor) was higher from hPMSCs than it was from other cells. FACS and Western blot analyses showed t

SUBMITTER: Ding C 

PROVIDER: S-EPMC7041770 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature